scholarly journals Cause-Specific Life Expectancies After 35 Years of Age for Human Immunodeficiency Syndrome-Infected and Human Immunodeficiency Syndrome-Negative Individuals Followed Simultaneously in Long-term Cohort Studies, 1984–2008

2013 ◽  
Vol 177 (2) ◽  
pp. 116-125 ◽  
Author(s):  
Nikolas Wada ◽  
Lisa P. Jacobson ◽  
Mardge Cohen ◽  
Audrey French ◽  
John Phair ◽  
...  
Oncotarget ◽  
2016 ◽  
Vol 7 (32) ◽  
pp. 50914-50926 ◽  
Author(s):  
Yun-Jung Choi ◽  
Kiho Lee ◽  
Woo-Jin Park ◽  
Deug-Nam Kwon ◽  
Chankyu Park ◽  
...  

2018 ◽  
Vol 44 (suppl_1) ◽  
pp. S415-S416
Author(s):  
Matti Isohanni ◽  
Jouko Miettunen ◽  
Erika Jääskeläinen ◽  
Jani Moilanen ◽  
Anja Hulkko ◽  
...  

1986 ◽  
Vol 4 (5) ◽  
pp. 737-743 ◽  
Author(s):  
P S Gill ◽  
P R Meyer ◽  
Z Pavlova ◽  
A M Levine

Acute lymphocytic leukemia (ALL) is a heterogeneous group of disorders, clinically, immunologically, and pathologically. ALL of a B cell phenotype (B-ALL) is the least common. We have studied ten adult patients with B-ALL, none of whom had a tumor mass. The median age was 56 years (range, 30 to 90). A history of an altered immune state was noted in four cases: a distant history of Hashimoto's thyroiditis in one, pregnancy in one, and acquired immunodeficiency syndrome in two. Two patients presented with CNS involvement, and in two additional patients CNS leukemia developed during the course of disease. By the French-American-British (FAB) classification system, L3 leukemic morphology was present in nine, whereas L2 was present in one. Circulating leukemic blasts varied from less than 500/dL to greater than 15,000/dL. Eight patients were thrombocytopenic, and eight were anemic at presentation. Immunologic marker studies on leukemic blasts revealed monoclonal kappa light chain marking in nine and monoclonal lambda in one. Following chemotherapy, complete remission was achieved in three patients, two of whom experienced relapse within 9 months. The median survival for the group was 3 months, and only one patient experienced long-term, disease-free survival. We conclude that B-ALL in the adult presents with the classic L3 morphologic picture in the majority and is associated with extremely short survival.


2017 ◽  
Vol 8 (1) ◽  
Author(s):  
T. Schober ◽  
T. Magg ◽  
M. Laschinger ◽  
M. Rohlfs ◽  
N. D. Linhares ◽  
...  

1995 ◽  
Vol 84 (02) ◽  
pp. 95-101 ◽  
Author(s):  
Andrew Vickers

AbstractCritical appraisal of a scientific trial involves deciding on its internal validity— whether the hypothesis has been correctly accepted or rejected—and its external validity—the extent to which the trial's findings can be generalized. Discourse on homoeopathic research has focused on the former at the expense of the latter and an analysis of homoeopathic research demonstrates that it has low external validity. One solution would be to split the research process in two. Large scale, triple-blind trials could be used to determine the extent to which the action of homoeopathy may be explained by placebo. Importantly, no assessment of external validity would be made. Audit and cohort studies could then be used to examine questions usually associated with external validity, such as the conditions most suitable for treatment and the long-term clinical value of homoeopathy.


2018 ◽  
Vol 28 (10) ◽  
pp. 930-931 ◽  
Author(s):  
Susanna Ritchie-McLean ◽  
Sally Wilmshurst

Sign in / Sign up

Export Citation Format

Share Document